These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 25519157)
1. Molecular dynamics simulation studies of the wild type and E92Q/N155H mutant of Elvitegravir-resistance HIV-1 integrase. Chen Q; Cheng X; Wei D; Xu Q Interdiscip Sci; 2015 Mar; 7(1):36-42. PubMed ID: 25519157 [TBL] [Abstract][Full Text] [Related]
2. Molecular dynamics simulation studies of the wild type and E92Q/N155H mutant of Elvitegravir-resistance HIV-1 integrase. Chen Q; Cheng X; Wei D; Xu Q Interdiscip Sci; 2014 Nov; ():. PubMed ID: 25373632 [TBL] [Abstract][Full Text] [Related]
3. Impact of resistance mutations on inhibitor binding to HIV-1 integrase. Chen Q; Buolamwini JK; Smith JC; Li A; Xu Q; Cheng X; Wei D J Chem Inf Model; 2013 Dec; 53(12):3297-307. PubMed ID: 24205814 [TBL] [Abstract][Full Text] [Related]
4. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity. Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578 [TBL] [Abstract][Full Text] [Related]
5. Molecular dynamics approaches estimate the binding energy of HIV-1 integrase inhibitors and correlate with in vitro activity. Johnson BC; Métifiot M; Pommier Y; Hughes SH Antimicrob Agents Chemother; 2012 Jan; 56(1):411-9. PubMed ID: 22037850 [TBL] [Abstract][Full Text] [Related]
6. Unravelling the dynamics of selection of multiresistant variants to integrase inhibitors in an HIV-1-infected child using ultra-deep sequencing. Stefic K; Salmona M; Capitao M; Splittgerber M; Maakaroun-Vermesse Z; Néré ML; Bernard L; Chaix ML; Barin F; Delaugerre C J Antimicrob Chemother; 2017 Mar; 72(3):850-854. PubMed ID: 27999055 [TBL] [Abstract][Full Text] [Related]
8. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Marinello J; Marchand C; Mott BT; Bain A; Thomas CJ; Pommier Y Biochemistry; 2008 Sep; 47(36):9345-54. PubMed ID: 18702518 [TBL] [Abstract][Full Text] [Related]
9. Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions. Andreatta KN; Miller MD; White KL Antimicrob Agents Chemother; 2016 Feb; 60(2):757-65. PubMed ID: 26574015 [TBL] [Abstract][Full Text] [Related]
10. Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. Abram ME; Hluhanich RM; Goodman DD; Andreatta KN; Margot NA; Ye L; Niedziela-Majka A; Barnes TL; Novikov N; Chen X; Svarovskaia ES; McColl DJ; White KL; Miller MD Antimicrob Agents Chemother; 2013 Jun; 57(6):2654-63. PubMed ID: 23529738 [TBL] [Abstract][Full Text] [Related]
11. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Malet I; Delelis O; Valantin MA; Montes B; Soulie C; Wirden M; Tchertanov L; Peytavin G; Reynes J; Mouscadet JF; Katlama C; Calvez V; Marcelin AG Antimicrob Agents Chemother; 2008 Apr; 52(4):1351-8. PubMed ID: 18227187 [TBL] [Abstract][Full Text] [Related]
13. Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro. Seki T; Suyama-Kagitani A; Kawauchi-Miki S; Miki S; Wakasa-Morimoto C; Akihisa E; Nakahara K; Kobayashi M; Underwood MR; Sato A; Fujiwara T; Yoshinaga T Antimicrob Agents Chemother; 2015 May; 59(5):2596-606. PubMed ID: 25691633 [TBL] [Abstract][Full Text] [Related]
14. Examining structural analogs of elvitegravir as potential inhibitors of HIV-1 integrase. Shah K; Gupta S; Mishra H; Sharma PK; Jayaswal A Arch Virol; 2014 Aug; 159(8):2069-80. PubMed ID: 24643333 [TBL] [Abstract][Full Text] [Related]
15. Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness. Hu Z; Kuritzkes DR J Acquir Immune Defic Syndr; 2010 Oct; 55(2):148-55. PubMed ID: 20634701 [TBL] [Abstract][Full Text] [Related]
16. Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C Integrase-Dolutegravir binding. Chitongo R; Obasa AE; Mikasi SG; Jacobs GB; Cloete R PLoS One; 2020; 15(5):e0223464. PubMed ID: 32379830 [TBL] [Abstract][Full Text] [Related]
17. Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics. DeAnda F; Hightower KE; Nolte RT; Hattori K; Yoshinaga T; Kawasuji T; Underwood MR PLoS One; 2013; 8(10):e77448. PubMed ID: 24146996 [TBL] [Abstract][Full Text] [Related]
18. Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239. Hassounah SA; Liu Y; Quashie PK; Oliveira M; Moisi D; Brenner BG; Sandstrom PA; Mesplède T; Wainberg MA J Virol; 2015 Dec; 89(23):12002-13. PubMed ID: 26378179 [TBL] [Abstract][Full Text] [Related]
19. Exploring the molecular mechanism of cross-resistance to HIV-1 integrase strand transfer inhibitors by molecular dynamics simulation and residue interaction network analysis. Xue W; Jin X; Ning L; Wang M; Liu H; Yao X J Chem Inf Model; 2013 Jan; 53(1):210-22. PubMed ID: 23231029 [TBL] [Abstract][Full Text] [Related]
20. Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137. Hombrouck A; Voet A; Van Remoortel B; Desadeleer C; De Maeyer M; Debyser Z; Witvrouw M Antimicrob Agents Chemother; 2008 Jun; 52(6):2069-78. PubMed ID: 18378713 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]